SecBot SecBot
8-K ·Filed Apr 20, 2026

ACOG

Alpha Cognition Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001213900-26-045668
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor upcoming proxy filings for full director compensation details and potential committee assignments. No immediate financial impact expected, but investor sentiment may improve given Sensenig's strong biopharma CFO background.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
ACOG ▲ +21.37% at T+60d
NEUTRAL call +21.37% · α vs SPY +14.47% · entry $6.88 → $8.35
Entry = T+0 close
Apr 20, 2026
via day close
T+1d
+1.60%
call +1.60% · α +0.58%
$6.99
settled 6mo ago
T+5d
-9.88%
call -9.88% · α -10.97%
$6.20
settled 6mo ago
T+20d
-16.42%
call -16.42% · α -21.34%
$5.75
settled 5mo ago
T+60d
+21.37%
call +21.37% · α +14.47%
$8.35
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Alpha Cognition Inc. appointed Bethany Sensenig to its board of directors on April 15, 2026. Sensenig brings extensive biopharma CFO experience from Radius Health, 9 Meters Biopharma, and Biogen, and will receive an initial equity grant of 5,489 RSUs and 6,991 stock options, both vesting after one year.

Key Facts

  • Bethany Sensenig appointed to board on April 15, 2026
  • Prior CFO roles at Radius Health, 9 Meters Biopharma, Minovia Therapeutics, and Biogen
  • Also serves on boards of Supernus Pharmaceuticals (SUPN) and KalVista Pharmaceuticals (KALV)
  • Received 5,489 restricted stock units and 6,991 stock options with $6.65 exercise price
  • All equity awards vest one year after grant date

Financial Impact

Approximately $83,000 in initial equity grants based on current stock price and grant size

share countequity compensation expense

Risk Factors

  • Minimal near-term risk; equity grant could lead to modest dilution upon vesting
  • No operational changes indicated with this appointment

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-045668
Document: 0001213900-26-045668-index-headers.html0001213900-26-045668
Document: 0001213900-26-045668-index.html0001213900-26-045668
Document: 0001213900-26-045668.txt0001213900-26-045668
7 reports for ACOG
Performance horizon
75% Hit rate @ T+5 3 of 4 directional calls Went positive at some point 3 of 4 best @ T+60▲ +50.08%May 19, 2026
Filters
Rows
Reports for ACOG — sortable, filterable
TypeNow
Sep 28, 2026
28d ago
Insider Buy
BULLISH ★ 5/10
$8.71 $8.98▲ +3.10%▲ +1.15%$8.30 (−4.71%)
Sep 23, 2026
4w ago
SC 13G
NEUTRAL ★ 3/10
$8.57 $8.70▲ +1.52%▲ +1.93%$8.30 (−3.15%)
Sep 16, 2026
5w ago
Insider Buy
BULLISH ★ 4/10
$8.85 $8.57▼ −3.16%▼ −3.76%$8.30 (−6.21%)
Aug 24, 2026
9w ago
Insider Buy
NEUTRAL ★ 3/10
$9.75 $9.27▼ −4.92%▼ −5.39%$8.30 (−14.87%)
May 19, 2026
22w ago
Insider Cluster
BULLISH ★ 5/10
$5.89 $5.94▲ +0.85%▼ −0.95%$8.30 (+40.92%)
Apr 20, 2026
27w ago
8-K
NEUTRAL ★ 3/10
$6.88 $6.20▼ −9.88%▼ −10.97%$8.30 (+20.64%)
Apr 14, 2026
27w ago
8-K
BULLISH ★ 7/10
$6.75 $6.99▲ +3.56%▲ +1.92%$8.30 (+22.96%)
Showing 7 of 7

US Market Status

Market Closed — Opens in 9h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 20, 2026